• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)

PRODUCT FILTERS

REGION

370
58
43
41
20

COUNTRY

40
8
5
5
4

PRICE

136
413
509
1,026

PUBLISHED

16
60
287
1,026

PRODUCT TYPE

993
17
11
4
1

Central Nervous System

In 2012 major changes might revolutionize the treatment of multiple sclerosis, as Gilenya, the first novel drug in five years, will be joined by three new products: BG-12, Aubagio, and Lemtrada. Recent exciting developments in drug discovery might also enhance the hopes of those fighting against Alzheimer.

Great commercial and scientific opportunities are to be found in similar battles against a range of diseases and neurodegenerative disorders, e.g. Parkinson’s disease, schizophrenia, migraine, insomnia, epilepsy, etc.

A wide selection of industry reports, scientific journals and academic textbooks in this section allow readers to explore every conceivable facet of this industry, such as market trends, industry forecasts, new drugs in development, the latest research & development, patent applications, and licensing strategies.

Key players featured in our publications include Biogen Idec, Sanofi, Genzyme, and many more. Show Less
Read more

PRODUCT TITLE

Moderate Pain - Pipeline Review, H2 2013

Moderate Pain - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Moderate Pain - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides...

November 2013
FROM

EpiCast Report: Trigeminal Neuralgia - Epidemiology Forecast to 2022

EpiCast Report: Trigeminal Neuralgia - Epidemiology Forecast to 2022 Summary Trigeminal neuralgia, also called tic douloureux, is a chronic nerve disorder characterized by severe facial nerve. The...

November 2013
FROM

EpiCast Report: Schizophrenia - Epidemiology Forecast to 2022

EpiCast Report: Schizophrenia - Epidemiology Forecast to 2022 Summary Schizophrenia is a chronic, severe, and disabling group of psychotic disorders characterized by fundamental disturbances of thinking...

November 2013
FROM

Global Multiple Sclerosis Market: Trends & Opportunities (2013-18)

The report titled 'Global Multiple Sclerosis Market: Trends & Opportunities (2013-18)' provides an insight into the market dynamics and various trends and opportunities associated with the global multiple...

November 2013
FROM

Post-Traumatic Stress Disorder (PTSD) Global Clinical Trials Review, H2, 2013

Post-Traumatic Stress Disorder (PTSD) Global Clinical Trials Review, H2, 2013 Summary Our clinical trial report, “Post-Traumatic Stress Disorder (PTSD) Global Clinical Trials Review, H2, 2013" provides...

October 2013
FROM

Opium (Opioid) Addiction Global Clinical Trials Review, H2, 2013

Opium (Opioid) Addiction Global Clinical Trials Review, H2, 2013 Summary Our clinical trial report, “Opium (Opioid) Addiction Global Clinical Trials Review, H2, 2013" provides data on the Opium (Opioid)...

October 2013
FROM

Schizophrenia Global Clinical Trials Review, H2, 2013

Schizophrenia Global Clinical Trials Review, H2, 2013 Summary Our clinical trial report, “Schizophrenia Global Clinical Trials Review, H2, 2013" provides data on the Schizophrenia clinical trial scenario....

October 2013
FROM

Parkinson's Disease Global Clinical Trials Review, H2, 2013

Parkinson's Disease Global Clinical Trials Review, H2, 2013 Summary Our clinical trial report, “Parkinson's Disease Global Clinical Trials Review, H2, 2013" provides data on the Parkinson’s Disease...

October 2013
FROM
Recent Developments in the CNS Drug Market Recent Developments in the CNS Drug Market - Product Thumbnail Image

Recent Developments in the CNS Drug Market

This report reviews the global market for CNS prescription drugs and recent developments within the marketplace, including collaborative agreements, recent clinical trial results and new product approvals...

October 2013
FROM

Relapsing Multiple Sclerosis (RMS) - Pipeline Review, H2 2013

Relapsing Multiple Sclerosis (RMS) - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Relapsing Multiple Sclerosis (RMS) - Pipeline Review, H2 2013', provides an overview of the indication’s...

October 2013
FROM

Friedreich Ataxia - Pipeline Review, H2 2013

Friedreich Ataxia - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Friedreich Ataxia - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report...

October 2013
FROM

Cerebral Palsy - Pipeline Review, H2 2013

Cerebral Palsy - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Cerebral Palsy - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides...

October 2013
FROM

Alcohol Addiction - Pipeline Review, H2 2013

Alcohol Addiction - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Alcohol Addiction - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report...

October 2013
FROM

Mild Cognitive Impairment - Pipeline Review, H2 2013

Mild Cognitive Impairment - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Mild Cognitive Impairment - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline....

October 2013
FROM

Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2013

Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2013', provides an overview of the indication’s...

October 2013
FROM

Acute Spinal Cord Injury - Pipeline Review, H2 2013

Acute Spinal Cord Injury - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Acute Spinal Cord Injury - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline....

October 2013
FROM

Rheumatoid Arthritis Pain - Pipeline Review, H2 2013

Rheumatoid Arthritis Pain - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Rheumatoid Arthritis Pain - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline....

October 2013
FROM

Other Central Nervous System Disorders - Pipeline Review, H2 2013

Other Central Nervous System Disorders - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Other Central Nervous System Disorders - Pipeline Review, H2 2013', provides an overview of the...

October 2013
FROM

Depression - Pipeline Review, H2 2013

Depression - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Depression - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides...

October 2013
FROM

Ischemic Stroke - Pipeline Review, H2 2013

Ischemic Stroke - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Ischemic Stroke - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report...

October 2013
FROM
Loading Indicator

Our Clients

Our clients' logos